In July, India’s domestic pharma retail market experienced an 11% growth, driven by sales of anti-infectives and pain-relief medicines due to increased flu and viral infections. Augmentin emerged as the top-selling brand with Rs 72 crore in sales. Acute therapies, including pain and anti-infectives, grew by 11%, while chronic medications increased by 12%.